Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-01-10
2006-01-10
McKane, Joseph K. (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S445000
Reexamination Certificate
active
06984660
ABSTRACT:
The invention relates to p-thienylbenzylamides of formula (I):in which R(1), R(2), R(3), R(4), R(5), R(6) and X have the meanings given in the description. The compounds of formula (I) are potent agonists of angiotensin-(1-7) receptors and are useful as pharmaceutically active compounds to treat and/or prevent hypertension; cardiac hypertrophy; cardiac insufficiency; coronary heart diseases, such as angina pectoris; and endothelial dysfunction or endothelial damage as a consequence, for example, of atherosclerotic processes or in association with diabetes mellitus.
REFERENCES:
patent: 6235766 (2001-05-01), Heitsch et al.
patent: 6429222 (2002-08-01), Heitsch et al.
patent: 0 512 675 (1992-11-01), None
patent: 0 513 979 (1992-11-01), None
patent: 2 281 298 (1995-03-01), None
patent: WO 00/68226 (2000-11-01), None
Loot et al.,Circulation, 105: 1548-1550, 2002.
“The Endothelium as a Target and Mediator of Cardiovascular Disease,”European Journal of Clinical Investigation, 23: 670-685 (1993).
Benter, et al., “Antihypertensive Actions of Angiotensin-(1-7) in Spontaneously Hypertensive Rats,”Journal of Physiology, 269(1): H313-H319 (1995).
Benter, et al., “Cardiovascular Actions of Angiotensin(1-7),”Peptides, 14(4): 679-684 (1993).
Brosnihan, “Effect of the Angiotension-(107) Peptide on Nitric Oxide Release,”The American Journal of Cardiology, 82(10A): 17S-19S (1998).
Brosnihan, et al., “Angiotensin-(1-7) Dilates Canine Coronary Arteries Through Kinins and Nitric Oxide,”Hypertension, 27(3): 523-528 (1996).
Deprez, et al., “Sulfonylureas and Sulfonylcarbamates as New Non-Tetrazole Angiotensin II Receptor Antagonists. Discovery of a Highly Potent Orally Active (Imidazolylbiphenylyl) Sulfonylurea (HR 720),”Journal of Medicinal Chemistry, 38 (13): 2357-2377 (1995).
Ferrario, et al., “Angiotensin-(1-7): A Bioactive Fragment of the Renin-angiotensin System,”Regulatory Peptides, 78: 13-18 (1998).
Ferrario, et al., “Angiotensin-(1-7): A New Hormone of the Angiotensin System,”Hypertension, 18(5): 126-133 (1991).
Ferrario, et al., “Charaterization of Angiotensin-(1-7) in the Urine of Normal and Essential Hypertensive Subjects,”Hypertension, 11(1): 137-146 (1998).
Ferrario, et al., “Counterregulatory Actions of Angiotensin-(1-7),”Hypertension, 30(3): 535-541 (1997).
Freeman, et al, “Angiotensin-(1-7) Inhibits Vascular Smooth Muscle Cell Growth,”Hypertension, 28(1): 104-108 (1996).
Handa, et al., “Renal Actions of Angiotensin-(1-7): In Vivo and In Vitro Studies,”American Journal of Physiology, 270(1): 141-147 (1996).
Heitsch, et al., “3-N- Methylviphenylsulfonylurea and -Carbamate Substituted Imidazo [4,5-b] Pyridines. Potent Antagonists of the ANG II AT1Receptors,”Bioorganic&Medicinal Chemistry, 5(4): 673-678 (1997).
Heitsch, et al., “Synthesis of the Imidazole-Derived AT1-Selective ANG II Receptor Antagonist HR 720 Utilizing Reductive Amination as Key Step,”Journal of Synthetic Organic Chemistry, 11: 1325-1330 (1990).
Iyer, et al, “Vasodepressor Actions of Angiotensin-(17) Unmasked During Combined Treatment with Lisinopril and Losartan,”Hypertension, 31(2): 699-705 (1998).
Jaiswal, et al., “Stimulation of Eendothelial Cell Porstaglandin Production by Angiotensin Peptides,”Hypertension, 19(2): 49-55 (1992).
Lane, “Sodium Cyanoborohydride—A Highly Selective Reducing Agent for Organic Functional Groups,”International Journal of Methods in Synthetic Organic Chemistry, 3: 135-146 (1975).
Matsumura, et al., “Stereoselective Syntheses of Solenopsin A and B,”Tetrahedron Letters, 23(18): 1929-1932 (1982).
Miyaura, et al., “The Palladium-Catalyzed Cross-Coupling Reaction of Phenylvoronic Acid With Haloarenes in the Presence of Bases,”Synthetic Communications, 11(7): 513-519 (1981).
Moriarty, et al., “A Revised Structure for the Marine Bromindole Derivative Citorellamine,”Tetrahedron Letters, 28(7): 749-752 (1987).
Santos, et al., “Charaterization of a New Angiotensin Antagonist Selective for Angiotensin-(1-7): Evidence That the Actions of Angiotensin-(1-7) are Mediated by Specific Angiotensin Receptors,”Brain Research Bulletin, 35(4): 293-298 (1994).
Strawn, et al., “Angiotensin-(1-7) Reduces Smooth Muscle Growth After Vascular Injury,”Hypertension, 33(1): 207-211 (1999).
Tallant, et al, “Bovine Aortic Endothelial Cells Contain an Angiotensin-(1-7) Receptor,”Hypertension, 29(1) 388-393 (1997).
Tran, et al., “Angiotensin-(1-7) and the Rat Aorta: Modulation by the Endothelium,”Journal of Cardiovascular Pharmacology, 30(5): 676-682 (1997).
Wiemer, et al., “Production of Cyclic GMP via Activation of B1 and B2 Kinin Receptors in Cultured Bovine Aortic Endothelial Cells,”The Journal of Pharmacology and Experimental Therapeutics, 262(2): 729-733 (1992).
Anderson Rebecca
Aventis Pharma Deutschland GmbH
Finnegan Henderson Farabow Garrett & Dunner L.L.P.
McKane Joseph K.
LandOfFree
P-thienylbenzylamides as agonists of angiotensin-(1-7)... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with P-thienylbenzylamides as agonists of angiotensin-(1-7)..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and P-thienylbenzylamides as agonists of angiotensin-(1-7)... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3533032